Search

Your search keyword '"Merajver, Sofia D."' showing total 895 results
Start Over Author "Merajver, Sofia D."
895 results on '"Merajver, Sofia D."'

2. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

Author

Daly, Mary B, Pal, Tuya, Maxwell, Kara N, Churpek, Jane, Kohlmann, Wendy, AlHilli, Zahraa, Arun, Banu, Buys, Saundra S, Cheng, Heather, Domchek, Susan M, Friedman, Susan, Giri, Veda, Goggins, Michael, Hagemann, Andrea, Hendrix, Ashley, Hutton, Mollie L, Karlan, Beth Y, Kassem, Nawal, Khan, Seema, Khoury, Katia, Kurian, Allison W, Laronga, Christine, Mak, Julie S, Mansour, John, McDonnell, Kevin, Menendez, Carolyn S, Merajver, Sofia D, Norquist, Barbara S, Offit, Kenneth, Rash, Dominique, Reiser, Gwen, Senter-Jamieson, Leigha, Shannon, Kristen Mahoney, Visvanathan, Kala, Welborn, Jeanna, Wick, Myra J, Wood, Marie, Yurgelun, Matthew B, Dwyer, Mary A, and Darlow, Susan D

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Oncology and Carcinogenesis, Prostate Cancer, Genetic Testing, Ovarian Cancer, Cancer, Orphan Drug, Pancreatic Cancer, Digestive Diseases, Rare Diseases, Urologic Diseases, Breast Cancer, Genetics, Prevention, Aetiology, 2.1 Biological and endogenous factors, Male, Female, Humans, Germ-Line Mutation, Breast Neoplasms, Genetic Predisposition to Disease, Risk Factors, Ovarian Neoplasms, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.

Published
2023

6. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Author

Daly, Mary B, Pal, Tuya, Berry, Michael P, Buys, Saundra S, Dickson, Patricia, Domchek, Susan M, Elkhanany, Ahmed, Friedman, Susan, Goggins, Michael, Hutton, Mollie L, Karlan, Beth Y, Khan, Seema, Klein, Catherine, Kohlmann, Wendy, Kurian, Allison W, Laronga, Christine, Litton, Jennifer K, Mak, Julie S, Menendez, Carolyn S, Merajver, Sofia D, Norquist, Barbara S, Offit, Kenneth, Pederson, Holly J, Reiser, Gwen, Senter-Jamieson, Leigha, Shannon, Kristen Mahoney, Shatsky, Rebecca, Visvanathan, Kala, Weitzel, Jeffrey N, Wick, Myra J, Wisinski, Kari B, Yurgelun, Matthew B, Darlow, Susan D, and Dwyer, Mary A

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Breast Cancer, Orphan Drug, Pancreatic Cancer, Genetic Testing, Rare Diseases, Prevention, Genetics, Ovarian Cancer, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Breast Neoplasms, Female, Genes, BRCA1, Genes, BRCA2, Genetic Counseling, Genetic Predisposition to Disease, Humans, Male, Mutation, Ovarian Neoplasms, Pancreatic Neoplasms, CGC, LCGC, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.

Published
2021

7. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer

Author

Achreja, Abhinav, Yu, Tao, Mittal, Anjali, Choppara, Srinadh, Animasahun, Olamide, Nenwani, Minal, Wuchu, Fulei, Meurs, Noah, Mohan, Aradhana, Jeon, Jin Heon, Sarangi, Itisam, Jayaraman, Anusha, Owen, Sarah, Kulkarni, Reva, Cusato, Michele, Weinberg, Frank, Kweon, Hye Kyong, Subramanian, Chitra, Wicha, Max S., Merajver, Sofia D., Nagrath, Sunitha, Cho, Kathleen R., DiFeo, Analisa, Lu, Xiongbin, and Nagrath, Deepak

Published
2022
Full Text
View/download PDF

10. Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry

Author

Jiagge, Evelyn M., Ulintz, Peter J., Wong, Shukmei, McDermott, Sean P., Fossi, Sabrina I., Suhan, Tahra K., Hoenerhoff, Mark J., Bensenhaver, Jessica M., Salem, Barbara, Dziubinski, Michele, Oppong, Joseph K., Aitpillah, Francis, Ishmael, Kyei, Osei-Bonsu, Ernest, Adjei, Ernest, Baffour, Awuah, Aldrich, Jessica, Kurdoglu, Ahmet, Fernando, Kurt, Craig, David W., Trent, Jeff M., Li, Jun, Chitale, Dhananjay, Newman, Lisa A., Carpten, John D., Wicha, Max S., and Merajver, Sofia D.

Published
2021
Full Text
View/download PDF

11. A Lipopeptidomimetic of Transcriptional Activation Domains Selectively Disrupts the Coactivator Med25 Protein–Protein Interactions.

Author

Pattelli, Olivia N., Valdivia, Estefanía Martínez, Beyersdorf, Matthew S., Regan, Clint S., Rivas, Mónica, Hebert, Katherine A., Merajver, Sofia D., Cierpicki, Tomasz, and Mapp, Anna K.

Subjects
TRIPLE-negative breast cancer, AMINO acid sequence, PROTEIN-protein interactions
Abstract

Short amphipathic peptides are capable of binding to transcriptional coactivators, often targeting the same binding surfaces as native transcriptional activation domains. However, they do so with modest affinity and generally poor selectivity, limiting their utility as synthetic modulators. Here we show that incorporation of a medium‐chain, branched fatty acid to the N‐terminus of one such heptameric lipopeptidomimetic (LPPM‐8) increases the affinity for the coactivator Med25 >20‐fold (Ki >100 μM to 4 μM), rendering it an effective inhibitor of Med25 protein–protein interactions (PPIs). The lipid structure, the peptide sequence, and the C‐terminal functionalization of the lipopeptidomimetic each influence the structural propensity of LPPM‐8 and its effectiveness as an inhibitor. LPPM‐8 engages Med25 through interaction with the H2 face of its activator interaction domain and in doing so stabilizes full‐length protein in the cellular proteome. Further, genes regulated by Med25‐activator PPIs are inhibited in a cell model of triple‐negative breast cancer. Thus, LPPM‐8 is a useful tool for studying Med25 and mediator complex biology and the results indicate that lipopeptidomimetics may be a robust source of inhibitors for activator‐coactivator complexes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Risk factors for inflammatory and non-inflammatory breast cancer in North Africa

Author

Schairer, Catherine, Hablas, Ahmed, Eldein, Ibrahim AbdelBar Seif, Gaafar, Rabab, Rais, Henda, Mezlini, Amel, Ayed, Farhat Ben, Ayoub, Wided Ben, Benider, Abdellatif, Tahri, Ali, Khouchani, Mouna, Aboulazm, Dalia, Karkouri, Mehdi, Eissa, Saad, Bastawisy, Ahmed El, Yehia, Maha, Gadalla, Shahinaz M., Swain, Sandra M., Merajver, Sofia D., Brown, Linda Morris, Pfeiffer, Ruth M., and Soliman, Amr S.

Published
2020
Full Text
View/download PDF

19. Blood–Brain Barrier Remodeling in an Organ‐on‐a‐Chip Device Showing Dkk1 to be a Regulator of Early Metastasis

Author

Westerhof, Trisha M., primary, Yang, Benjamin A., additional, Merrill, Nathan M., additional, Yates, Joel A., additional, Altemus, Megan, additional, Russell, Liam, additional, Miller, Anna J., additional, Bao, Liwei, additional, Wu, Zhifen, additional, Ulintz, Peter J., additional, Aguilar, Carlos A., additional, Morikawa, Aki, additional, Castro, Maria G., additional, Merajver, Sofia D., additional, and Oliver, Christopher R., additional

Published
2023
Full Text
View/download PDF

21. Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa

Author

Schairer, Catherine, Hablas, Ahmed, Eldein, Ibrahim AbdelBar Seif, Gaafar, Rabab, Rais, Henda, Mezlini, Amel, Ayed, Farhat Ben, Ayoub, Wided Ben, Benider, Abdellatif, Tahri, Ali, Khouchani, Mouna, Aboulazm, Dalia, Karkouri, Mehdi, Eissa, Saad, Pfeiffer, Ruth M., Gadalla, Shahinaz M., Swain, Sandra M., Merajver, Sofia D., Brown, Linda Morris, and Soliman, Amr S.

Published
2019
Full Text
View/download PDF

24. TABLE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data S8 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

26. TABLE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

27. FIGURE 3 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data S3a and S3b from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

29. FIGURE 1 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

30. FIGURE 2 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

31. TABLE 3 from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

32. Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, primary, Ulintz, Peter, primary, Cheng, Xu, primary, Apfel, Athena, primary, Robinson, Dan, primary, Hopkins, Alex, primary, Kumar-Sinha, Chandan, primary, Wu, Yi-Mi, primary, Serhan, Habib, primary, Verbal, Kait, primary, Thomas, Dafydd, primary, Hayes, Daniel F., primary, Chinnaiyan, Arul M., primary, Baladandayuthapani, Veerabhadran, primary, Heth, Jason, primary, Soellner, Matthew B., primary, Merajver, Sofia D., primary, and Merrill, Nathan, primary

Published
2023
Full Text
View/download PDF

33. Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Author

Morikawa, Aki, primary, Li, Jinju, additional, Ulintz, Peter, additional, Cheng, Xu, additional, Apfel, Athena, additional, Robinson, Dan, additional, Hopkins, Alex, additional, Kumar-Sinha, Chandan, additional, Wu, Yi-Mi, additional, Serhan, Habib, additional, Verbal, Kait, additional, Thomas, Dafydd, additional, Hayes, Daniel F., additional, Chinnaiyan, Arul M., additional, Baladandayuthapani, Veerabhadran, additional, Heth, Jason, additional, Soellner, Matthew B., additional, Merajver, Sofia D., additional, and Merrill, Nathan, additional

Published
2023
Full Text
View/download PDF

34. Abstract 5592: Expansion and characterization on ALK positive NSCLC circulating tumor cells isolated using a size based inertial microfluidic Labyrinth device

Author

Chen, Yuru, primary, Fouladdel, Shamileh, additional, Ball, Harrison, additional, Cheng, Xu, additional, Bao, Liwei, additional, Serhan, Habib, additional, Liu, Albert, additional, Vandenburg, Bryce, additional, Goo, Laura, additional, Merrill, Nathan, additional, Udager, Aaron, additional, Qin, Angel, additional, Merajver, Sofia D., additional, and Nagrath, Sunitha, additional

Published
2023
Full Text
View/download PDF

35. Abstract 6037: Identification of collateral lethal targets in cancers using integrated machine learning and flux analysis platform for personalized metabolic therapy

Author

Achreja, Abhinav, primary, Jeon, Jin Heon, additional, Slayton, Mark, additional, Yu, Tao, additional, Animasahun, Olamide, additional, Nenwani, Minal, additional, Wuchu, Fulei, additional, Mittal, Anjali, additional, Lu, Xiongbin, additional, Merajver, Sofia D., additional, and Nagrath, Deepak, additional

Published
2023
Full Text
View/download PDF

37. Abstract 3921: Malic enzyme 2 identified as metabolic target in triple-negative breast cancers with increased serine biosynthesis

Author

Slayton, Mark D., primary, Jeon, Jin Heon, additional, Achreja, Abhinav, additional, Farah, Zackariah A., additional, Nilaj, Brisilda, additional, Eu, Yi-Hsien, additional, Lui, Alisa, additional, Collard, Mason, additional, Bao, Liwei, additional, Kleer, Celina, additional, Nagrath, Deepak, additional, and Merajver, Sofia D., additional

Published
2023
Full Text
View/download PDF

44. Appendix from A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer

Author

Bhatia, Smita, primary, Palomares, Melanie R., primary, Hageman, Lindsey, primary, Chen, Yanjun, primary, Landier, Wendy, primary, Smith, Kandice, primary, Umphrey, Heidi, primary, Reich, Caroline A., primary, Zamora, Kathryn W., primary, Armenian, Saro H., primary, Bevers, Therese B., primary, Blaes, Anne, primary, Henderson, Tara, primary, Hodgson, David, primary, Hudson, Melissa M., primary, Korde, Larissa A., primary, Melin, Susan A., primary, Merajver, Sofia D., primary, Overholser, Linda, primary, Pruthi, Sandhya, primary, Wong, F. Lennie, primary, and Garber, Judy E., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table S1 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

Author

Gilani, Rabia A., primary, Phadke, Sameer, primary, Bao, Li Wei, primary, Lachacz, Eric J., primary, Dziubinski, Michele L., primary, Brandvold, Kristoffer R., primary, Steffey, Michael E., primary, Kwarcinski, Frank E., primary, Graveel, Carrie R., primary, Kidwell, Kelley M., primary, Merajver, Sofia D., primary, and Soellner, Matthew B., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figures S1-S12 from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

Author

Gilani, Rabia A., primary, Phadke, Sameer, primary, Bao, Li Wei, primary, Lachacz, Eric J., primary, Dziubinski, Michele L., primary, Brandvold, Kristoffer R., primary, Steffey, Michael E., primary, Kwarcinski, Frank E., primary, Graveel, Carrie R., primary, Kidwell, Kelley M., primary, Merajver, Sofia D., primary, and Soellner, Matthew B., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Materials and Methods from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

Author

Gilani, Rabia A., primary, Phadke, Sameer, primary, Bao, Li Wei, primary, Lachacz, Eric J., primary, Dziubinski, Michele L., primary, Brandvold, Kristoffer R., primary, Steffey, Michael E., primary, Kwarcinski, Frank E., primary, Graveel, Carrie R., primary, Kidwell, Kelley M., primary, Merajver, Sofia D., primary, and Soellner, Matthew B., primary

Published
2023
Full Text
View/download PDF

48. Protocol from A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer

Author

Bhatia, Smita, primary, Palomares, Melanie R., primary, Hageman, Lindsey, primary, Chen, Yanjun, primary, Landier, Wendy, primary, Smith, Kandice, primary, Umphrey, Heidi, primary, Reich, Caroline A., primary, Zamora, Kathryn W., primary, Armenian, Saro H., primary, Bevers, Therese B., primary, Blaes, Anne, primary, Henderson, Tara, primary, Hodgson, David, primary, Hudson, Melissa M., primary, Korde, Larissa A., primary, Melin, Susan A., primary, Merajver, Sofia D., primary, Overholser, Linda, primary, Pruthi, Sandhya, primary, Wong, F. Lennie, primary, and Garber, Judy E., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure Legends from UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer

Author

Gilani, Rabia A., primary, Phadke, Sameer, primary, Bao, Li Wei, primary, Lachacz, Eric J., primary, Dziubinski, Michele L., primary, Brandvold, Kristoffer R., primary, Steffey, Michael E., primary, Kwarcinski, Frank E., primary, Graveel, Carrie R., primary, Kidwell, Kelley M., primary, Merajver, Sofia D., primary, and Soellner, Matthew B., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results